Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.80
+0.02710.08%
Post-market: 33.77-0.0271-0.08%16:10 EDT
Volume:222
Turnover:8K
Market Cap:13.52M
PE:- -
High:33.80
Open:33.77
Low:33.80
Close:33.77
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.14
T/O Rate:0.06%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Oct 01

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Oct 01

Nexsen reshapes leadership to drive growth in point-of-care diagnostics

TIPRANKS
·
Oct 01

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 01

Grindr to acquire Freddie for $250M in cash and stock

TIPRANKS
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Gilead put volume heavy and directionally bearish

TIPRANKS
·
Oct 01

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Oct 01

Lilly's Closely Watched Obesity Combination Therapy Shows Greater Weight Loss in Mid-Stage Trial

Deep News
·
Oct 01

Verici Dx boosts Tutivia growth and expands transplant diagnostics footprint

TIPRANKS
·
Oct 01

Edwards Lifesciences' TAVR Evaluation in Moderate Aortic Stenosis Among Most Awaited Clinical Trial Readouts, Oppenheimer Says

MT Newswires Live
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30